Acne characteristics in Latin American patients and the potential role of trifarotene.
暂无分享,去创建一个
R. Chavda | E. C. Cohen Sabban | L. Almeida | Ricardo Castillo | L. Fierro-Arias | M. A. D. da Rocha
[1] A. Alexis,et al. Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice , 2021, American Journal of Clinical Dermatology.
[2] B. Dréno,et al. The Personalised Acne Care Pathway—Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts , 2021, JAAD international.
[3] Susan C. Taylor,et al. The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation , 2021, American Journal of Clinical Dermatology.
[4] G. Webster,et al. 50 Years of Topical Retinoids for Acne: Evolution of Treatment , 2021, American Journal of Clinical Dermatology.
[5] S. Puig,et al. Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] B. Dréno,et al. The Skin Microbiome: A New Actor in Inflammatory Acne , 2020, American Journal of Clinical Dermatology.
[7] Jianyun Lu,et al. Roles of inflammation factors in melanogenesis , 2020, Molecular medicine reports.
[8] L. Kemény,et al. Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] M. Gooderham,et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. , 2019, Journal of the American Academy of Dermatology.
[10] B. Dréno,et al. Atrophic scar formation in patients with acne involves long‐acting immune responses with plasma cells and alteration of sebaceous glands , 2018, The British journal of dermatology.
[11] B. Dréno,et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor‐γ agonist trifarotene , 2018, The British journal of dermatology.
[12] Jerry Tan,et al. Treating Acne in Patients With Skin of Color. , 2018, Seminars in cutaneous medicine and surgery.
[13] E. Thoreau,et al. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. , 2018, Bioorganic & medicinal chemistry letters.
[14] H. Gollnick,et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne , 2018, Journal of the American Academy of Dermatology.
[15] F. Penedo,et al. Recognizing Latinos’ range of skin pigment and phototypes to enhance skin cancer prevention , 2017, Pigment cell & melanoma research.
[16] J. Leyden,et al. Prevalence and Risk Factors of Acne Scarring Among Patients Consulting Dermatologists in the USA , 2017, Journal of drugs in dermatology : JDD.
[17] R. Poulton,et al. Cumulative mental health consequences of acne: 23‐year follow‐up in a general population birth cohort study , 2016, The British journal of dermatology.
[18] J. Leyden,et al. Guidelines of care for the management of acne vulgaris. , 2016, Journal of the American Academy of Dermatology.
[19] M. Kawashima,et al. Prevalence of scars and “mini‐scars”, and their impact on quality of life in Japanese patients with acne , 2015, The Journal of dermatology.
[20] G. Magalon,et al. Cicatrices chéloïdes : étude d’une série de cas , 2015 .
[21] T. S. Fröde,et al. Melasma and assessment of the quality of life in Brazilian women* , 2015, Anais brasileiros de dermatologia.
[22] S. Davis,et al. The quality of life impact of acne and rosacea compared to other major medical conditions. , 2014, Journal of drugs in dermatology : JDD.
[23] E. Bagatin,et al. Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. , 2014, Inflammation & allergy drug targets.
[24] A. McMichael,et al. Acne in Patients with Skin of Color: Practical Management , 2014, American Journal of Clinical Dermatology.
[25] G. Hillebrand,et al. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.
[26] L. Kircik. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. , 2011, Journal of drugs in dermatology : JDD.
[27] G. Fabbrocini,et al. Acne Scars: Pathogenesis, Classification and Treatment , 2010, Dermatology research and practice.
[28] Erica C Davis,et al. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. , 2010, The Journal of clinical and aesthetic dermatology.
[29] W. Gulliver,et al. Development and Validation of a Scale for Acne Scar Severity (SCAR-S) of the Face and Trunk , 2010, Journal of cutaneous medicine and surgery.
[30] V. Callender,et al. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. , 2010, The Journal of clinical and aesthetic dermatology.
[31] J. Elder,et al. Sun sensitivity in 5 US ethnoracial groups. , 2007, Cutis.
[32] Mallon,et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires , 1999, The British journal of dermatology.
[33] W. Cunliffe,et al. A clinical evaluation of acne scarring and its incidence , 1994, Clinical and experimental dermatology.
[34] B. Elewski,et al. The prevalence of acne in adults 20 years and older. , 2008, Journal of the American Academy of Dermatology.
[35] A. Kligman,et al. A clincohistopathological study of acne vulgaris in black females. , 1996 .